Hypertension, an AE characteristic of anti-VEGF inhibitors, was the most common (42.5%, n = 17; grade ≥ 3: 7.5%, n = 3), followed by proteinuria (40.0%, n = 16; grade ≥ 3: 15.0%, n = 6), edema (37.5%, n = 15), fever (32.5%, n = 13), fatigue (27.5%, n = 11), pruritus (25.0%, n = 10), decreased appetite (17.5%, n = 7), hand-foot skin reaction (12.5%, n = 5), rash(10.0%, n = 4), thyroid function abnormality (10.0%, n = 4), nasal bleeding (10.0%, n = 4), and stomatitis (10.0%, n = 4). This evidence concerns the gene VEGFA and hypertensive disorder.